Skip to main
EVMN

Evommune Inc (EVMN) Stock Forecast & Price Target

Evommune Inc (EVMN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evommune Inc's clinical-stage pipeline, highlighted by candidates EVO756 and EVO301, demonstrates promising results in treating chronic inflammatory diseases, particularly chronic spontaneous urticaria and atopic dermatitis, which may lead to significant revenue growth. The company's novel molecular structure appears to enhance the therapeutic profile of its treatments, with a notable 70% improvement rate among patients in early trials and expectations of translating this efficacy to atopic dermatitis, thus expanding commercial opportunities. Additionally, the potential expansion into ulcerative colitis signifies a strategic move into another high-value market, further supporting a positive long-term financial outlook for the company as it aims for first-mover advantage in targeting IL-18 for these conditions.

Bears say

Evommune Inc faces a negative outlook primarily due to anticipated challenges in market penetration and competition for its pipeline products, EVO756 and EVO301, which are expected to fall short of peak sales forecasts. The company's clinical trial results indicate a reduction in treatment efficacy, with significant portions of patients experiencing limited response, highlighting potential difficulties in achieving widespread adoption in a competitive landscape. Additionally, concerns regarding slower market uptake, potential patent challenges, and risks of equity dilution further compound the uncertainty surrounding Evommune's financial prospects.

Evommune Inc (EVMN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evommune Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evommune Inc (EVMN) Forecast

Analysts have given Evommune Inc (EVMN) a Buy based on their latest research and market trends.

According to 6 analysts, Evommune Inc (EVMN) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evommune Inc (EVMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.